Advertisement

Is brain superoxide dismutase activity increased following chronic treatment with 1-deprenyl?

  • C. T. Lai
  • D. M. Zuo
  • P. H. Yu
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

L-deprenyl, a specific MAO-B inhibitor, has been proposed to possess a neuroprotective effect. The mechanism of such an effect is unclear. L-Deprenyl has been found to increase rat striatal Superoxide dismutase (SOD) activity, which inactivates singlet oxygen. It would be very interesting to know how such activation occurs and whether or not other MAO inhibitors also have such an effect. We have analyzed rat striatal SOD activity using a very sensitive nitrite method and an immunological procedure. The effect of different doses and time of treatment with 1-deprenyl and M-2-PP (2-pentyl-N-methyl-propargylamine), a new highly potent, selective and non-amphetamine-like MAO-B inhibitor, on the rat brain has been investigated. We were unable to detect any increase of SOD activity in the rat striata and cerebral cortex nor any increase in the concentration of immunoreactive SOD antibody in the cortex following chronic treatment with 1-deprenyl and M-2-PP. It remains to be substantiated as to whether or not 1-deprenyl can enhance SOD levels.

Keywords

Chronic Granulomatous Disease Parkinson Study Group Parkinsonian Brain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carrillo MC, Kanai S, Nokubo, Kitani K (1991) (-)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517–521.PubMedCrossRefGoogle Scholar
  2. Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO (1992) The ability of (-)-deprenyl to increase Superoxide dismutase activities in the rat tissue and brain region selective. Life Sci 50: 1985–1992.PubMedCrossRefGoogle Scholar
  3. Ceballos I, Lafon M, Agid J, Hirsch F, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase and Parkinson’s disease. Lancet i: 1035–1036.CrossRefGoogle Scholar
  4. Clow A, Hussain T, Glover V, Sandier M, Dexter DT, Walker M (1990) (−)-Deprenyl can induce soluble Superoxide dismutase in rat striata. J Neural Transm [Gen Sect] 86: 77–80.CrossRefGoogle Scholar
  5. Cohen G (1983) The pathobiolobgy of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 98–103.Google Scholar
  6. Colton CA, Gilbert DL (1987) Production of Superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223: 284–288.PubMedCrossRefGoogle Scholar
  7. Curnutte JT, Babior BM (1987) Chronic granulomatous disease. Adv Hum Genet 16: 229–297.PubMedGoogle Scholar
  8. Dexter DT, Carter CJ, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1986) Lipid peroxidation as cause of nigral cell death in Parkinson’s disease. Lancet: 639-640.Google Scholar
  9. Dexter DT, Carter CJ, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1989a) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389.PubMedCrossRefGoogle Scholar
  10. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989b) Increased nigra iron content and alternations in other metal ions occuring in brain in Parkinson’s disease. J Neurochem 52: 1830–1836.PubMedCrossRefGoogle Scholar
  11. Frank L (1982) Protection from O2 toxicity by pre-exposure to hypoxia: lung anti-oxidant enzyme role. J Appl Physiol 53: 475–482.PubMedGoogle Scholar
  12. Hirsch EC, Brandel J-P, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56: 446–451.PubMedCrossRefGoogle Scholar
  13. Knoll J (1988) The striatal dopamine dependency of lifespan in male rats. Longevity study with (—)deprenyl. Mech Ageing Dev 46: 237–262.PubMedCrossRefGoogle Scholar
  14. Knoll J, Dallo J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (—)deprenyl. Life Sci 45: 525–531.PubMedCrossRefGoogle Scholar
  15. Kramer K, Voss HP, Grimbergen JA, Timmerman H, Bast A (1987) The effect of ischemia and recirculation, hypoxia and recovery on anti-oxidant factors and ß-adrenoceptor density. Biochem Biophys Res Commun 149: 568–575.PubMedCrossRefGoogle Scholar
  16. Marttila RJ, Lorenz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson’s disease. Increase of Superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321–331.PubMedCrossRefGoogle Scholar
  17. Marttila RJ, Viljanen M, Toivonen E, Lorentz H, Rinne UK (1990) Superoxide dismutase-like activity in the Parkinson’s disease brain. Adv Neurol 53: 141–144.PubMedGoogle Scholar
  18. McCord JM, Fridorich I (1969) Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049–6055.PubMedGoogle Scholar
  19. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 47: 415–420.PubMedCrossRefGoogle Scholar
  20. Oyanagui Y (1984) Réévaluation of assay methods and establishment of kit for Superoxide dismutase activity. Anal Biochem 142: 290–296.PubMedCrossRefGoogle Scholar
  21. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371.CrossRefGoogle Scholar
  22. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in par-kinsonian brains. J Neurochem 52: 515–520.PubMedCrossRefGoogle Scholar
  23. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697.PubMedCrossRefGoogle Scholar
  24. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205.PubMedCrossRefGoogle Scholar
  25. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978–982.PubMedCrossRefGoogle Scholar
  26. Tetrud JW, Langston JW (1989) The effect of deprenyl (Selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522.PubMedCrossRefGoogle Scholar
  27. Wilkinson GN (1961) Statistical estimation in enzyme kinetics. Biochem J 80: 324–332.PubMedGoogle Scholar
  28. Yu PH, Davis BA, Boulton AA (1992) Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors. Prog Brain Res 94: 309–315.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • C. T. Lai
    • 1
  • D. M. Zuo
    • 1
  • P. H. Yu
    • 1
  1. 1.Neuropsychiatric Research Unit, Department of PsychiatryUniversity of SaskatchewanSaskatoonCanada

Personalised recommendations